Lek, a Sandoz company, is launching the Balans programme to promote healthier living
- The use of probiotics presents a natural and safe way to keep the balance of our intestinal microbiota, which is important for our health.
- As a part of Sandoz‘s efforts to promote healthier living, we are launching the Balans programme, which helps us maintain our inner and outer balance.
- This programme complements the 30 years of experience Lek, a Sandoz company, has in the field of microbiotics and its strong line of Linex probiotic products.
Probiotics help preserve the balance of the intestinal microbiota, as well as support the function of our immune and digestive system, and are thus important for our health. As a part of Lek, a Sandoz company’s, efforts to promote healthier living, we are launching the Balans programme (www.linex-probio.com), a custom-made lifestyle programme, based on simple but effective exercises, healthy recipes and tips and tricks that will guide people through their daily challenges.
The Balans lifestyle programme is designed for all those who wish to bring more balance and harmony into their daily routine. When we are in balance, we feel like we have our life under control; we effectively allocate time, control stress, exercise and eat well.
As we take care of our outside balance with the Balans programme, probiotics help us attain our inside balance.
At Lek, a Sandoz company, we have extensive experience in the field of probiotics and a strong family of probiotic products. The Linex line of probiotic products presents quality protection for balanced microbiota with its unique composition, quality and technological advancement. In 1982 Lek started the production of the probiotic product Linex in Prevalje, Slovenia and is celebrating over 30 years of its quality.
To this day, probiotics of Lek, a Sandoz company, have reached millions of people in more than 40 countries around the world. Linex products (Linex, Linex Forte and Linex Baby) are manufactured under the same high quality standards as our other medicinal products with decades of expertise and experience.
Linex was the number one brand in the probiotic category in Central and Eastern Europe in 20131.
1 Source: Nicholas Hall’s global OTC database’ DB6.
Central and Eastern Europe includes: Bulgaria, Croatia, Czech Republic, Hungary, Kazahstan, Lithuania, Poland, Romania, Russia, Slovakia, Slovenia, Turkey, and Ukraine.
- Binns N. Probiotics, prebiotics and the gut microbiota. ILSI Europe Concise Monograph Series, 2013. ILSI Europe International Life Sciences Institute.
- Cerf-Bensussan N. & Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nature review, Immunology, Oct 2010; 10: 735-744.
- Cryan JF. & Dinan TG Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nature reviews, Neuroscience Oct 2012; 13: 701-712.
- D’Arrigo T. Probiotics: what they are and what they can do for you. A patient’s guide from your doctor and The AGA Institute. The American Gastroenterological Association (http://www.gastro.org/patient-center/brochure_Probiotics.pdf).
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32